Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Felzartamab in Late Antibody-Mediated Renal Allograft Rejection – Phase 2 Pilot
2021-000545-40Phase 2Active
- Sponsor
- Medical University of Vienna
- Start
- Jun 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of felzartamab in Antibody-mediated rejection of kidney allograft (ABMR), sponsored by Medical University of Vienna. Primary endpoint: Safety and tolerability. Started Jun 2021; status: active.
02
Drugs
felzartamab
03
Conditions
Antibody-mediated rejection of kidney allograft (ABMR)
Beyond the preview
Go deeper on 2021-000545-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000545-40.